NCT05889871View on ClinicalTrials.gov

A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

916

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions
HR+/HER2-breast Cancer
Interventions
DRUG

Standard endocrine therapy plus Apatinib

Standard endocrine therapy plus Apatinib

All Listed Sponsors
lead

Fudan University

OTHER

NCT05889871 - A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer | Biotech Hunter | Biotech Hunter